Clinicopathologic evaluation of immunohistochemical CD147 and MMP-2 expression in differentiated thyroid carcinoma

Japanese Journal of Clinical Oncology

Volumn 38, Issue 8, 2008, Pages 528-533

  Tan, Hui ^a   Ye, Ke ^a   Wang, Zhiming ^a   Tang, Huihuan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

CD147; Clinicopathology; Differentiated thyroid carcinoma; Immunohistochemistry; MMP 2

Indexed keywords

CD147 ANTIGEN; GELATINASE A; PARAFFIN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CLINICAL FEATURE; CONTROLLED STUDY; DIFFERENTIATED THYROID CARCINOMA; ECTOPIC THYROID GLAND; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; ADENOCARCINOMA; CANCER STAGING; CELL MEMBRANE; CYTOPLASM; ENZYME IMMUNOASSAY; METABOLISM; MIDDLE AGED; PAPILLARY CARCINOMA; PATHOLOGY; PROGNOSIS; THYROID TUMOR;

ADENOCARCINOMA; ADENOCARCINOMA, FOLLICULAR; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD147; CARCINOMA, PAPILLARY; CELL MEMBRANE; CYTOPLASM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 51649124499     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn065     Document Type: Article

References (35)

1. Kini S, Saraf CK, Naik LP, Shah VB, Puranik GV, Vartakvi PK. Occult medullary carcinoma of thyroid with lymph node metastases: A case report. Acta Cytol 2008;52:105-8.
2. Salajegheh A, Petcu EB, Smith RA, Lam AK. Follicular variant of papillary thyroid carcinoma: A diagnostic challenge for clinicians and pathologists. Postgrad Med J 2008;84:78-82.
3. Pudney D, Lau H, Ruether JD, Falck V. Clinical experience of the multimodality management of anaplastic thyroid cancer and literature review. Thyroid 2007;17:1243-50.
4. Sugitani I, Fujimoto Y, Yamamoto N. Papillary thyroid carcinoma with distant metastases: Survival predictors and the importance of local control. Surgery 2008;143:35-42.
5. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: A 10-year follow-up study. J Clin Endocrinol Metab 2008;93:682-7.
6. Kremser R, Obrist P, Spizzo G, Erler H, Kendler D, Kemmler G, et al. Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease. Virchows Arch 2003;442:322-8.
7. Davidson B, Goldberg I, Berner A, Kristensen GB, Reich R. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastasis 2003;20: 161-9.
8. Tsai W-C, Chao Y-C, Sheu L-F, Lin Y-F, Nieh S, Chen A, et al. EMMPRIN and fascin overexpression associated with clinicopathologic parameters of pancreatobiliary adenocarcinoma in Chinese people. APMIS 2007;115:929-38.
9. Guo H, Li R, Zucker S, Toole BP. EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface. Cancer Res 2000;60:888-91.
10. Nabeshima K, Suzumiya J, Nagano M, Ohshima K, Toole BP, Tamura K, et al. Emmprin, a cell surface inducer of matrix metalloproteinases (MMPs), is expressed in T-cell lymphomas. J Pathol 2004;202:341-51.
11. Riethdorf S, Reimers N, Assmann V, Kornfeld JW, Terracciano L, Sauter G, et al. High incidence of EMMPRIN expression in human tumors. Int J Cancer 2006;119:1800-10.
12. Nabeshima K, Iwasaki H, Koga K, Hojo H, Suzumiya J, Kikuchi M. Emmprin (basigin/CD147): Matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int 2006;56:359-67.
13. Hedinger C, Williams ED, Sobin LH. Histological typing of thyroid tumours. Berlin: Springer 1988.
14. Tang Yi, Kesavan P, Marian T. Tumor-Stroma Interaction: Positive Feedback Regulation of Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) Expression and Matrix Metalloproteinase-Dependent Generation of Soluble EMMPRIN Molecular. Cancer Res 2004;2: 73-80.
15. Sier CornelisFM, Zuidwijk K, Zijlmans HJMAA, Hanemaaijer R, Mulder-Stapel AA, Prins FA, et al. EMMPRIN-induced MMP-2 activation cascade in human cervical squamous cell carcinoma. Int J Cancer 2006;118:2991-8.
16. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
17. Overall CM, McQuibban GA, Clark-Lewis I. Discovery of chemokine substrates for matrix metalloproteinases by exosite scanning: A new tool for degradomics. Biol Chem 2002;383:1059-66.
18. Sheu BC, Lien HC, Ho HN, Lin HH, Chow SN, Huang SC, et al. Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res 2003;63:6537-42.
19. Kato Y, Yamashita T, Ishikawa M. Relationship between expression of matrix metalloproteinase-2 and matrix metalloproteinase-9 and invasion ability of cervical cancer cells. Oncol Rep 2002;9:565-9.
20. Davidson B, Goldberg I, Kopolovic J, Lerner-Geva L, Gotlieb WH, Ben Baruch G, et al. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma-a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol 1999;73:372-82.
21. Moser PL, Kieback DG, Hefler L, Tempfer C, Neunteufel W, Gitsch G. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage IB cervical cancer. Anticancer Res 1999;19:4391-3.
22. Reimers Natalie, Zafrakas Kristine, Assmann Volker, Egen Cornelia, Riethdorf Lutz, Riethdorf Sabine, et al. Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res 2004;10:3422-8.
23. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002;21:2245-52.
24. Egeblad M, Werb Z. New function for the matrix metalloproteases in cancer progression. Nat Rev Cancer 2002;2:163-76.
25. Noguchi Y, Sato T, Hiratam M, Hara T, Ohama K, Ito A. Identification and characterization of extracellular matrix metalloproteinase inducer in human endometrium during the menstrual cycle in vivo and in vitro. J Clin Endocrinol Metab 2003;88:6063-72.
26. LI WEI, Alfaidy Nadia, Challis John RG. Expression of extracellular matrix metalloproteinase inducer in human placenta and fetal membranes at term labor. J Clin Endocrinol Metab 2006;89:2897-904.
27. Haseneen NA, Vaday GG, Zucker S, Foda HD. Mechanical stretch induces MMP-2 release and activation in lung endothelium: Role of EMMPRIN. Am J Physiol Lung Cell Mol Physiol 2003;284: L541-L547.
28. Davidson B, Givant-Horwitz V, Lazarovici P, Risberg B, Nesland JM, Trope CG, et al. Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): Co-expression in metastatic serous ovarian carcinoma. Clin Exp Metastasis 2003;20:621-31.
29. Campo E, Merino MJ, Liotta L. Distribution of the 72-kd type IV collagenase in nonneoplastic and neoplastic thyroid tissue. Hum Pathol 1992;23:1395-401.
30. Kameyama K. Expression of MMP-1 in the capsule of thyroid cancer relationship with invasiveness. Path Res Pract 1996;192:20-6.
31. Zedenius J, Stahle-Backdahl M, Enberg U. Stromal fibroblasts adjacent to invasive thyroid tumors: Expression of GelatinaseAbut not Stromelysin 3 mRNA. World J Surg 1996;20:101-6.
32. Nakamura H, Ueno H, Yamashita K. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. Cancer Res 1999;15:467-73.
33. Cho Mar K, Eimoto T, Tateyama H, Arai Y, Fujiyoshi Y, Hamaguchi M. Expression of matrix metalloproteinases in benign and malignant follicular thyroid lesions. Histopathology 2006;48:286-94.
34. Jin J-S, Hsieh D-S, Lin Y-F, Wang J-Y, Sheu L-F, Lee W-H. Increasing expression of extracellular matrix metalloprotease inducer in renal cell carcinoma: Tissue microarray analysis of immunostaining score with clinicopathological parameters. Int J Urol 2006;13:573-80.
35. Zhang W, Erkan M, Abiatari I, Giese NA, Felix K, Kayed H, et al. Expression of Extracellular Matrix Metalloproteinase Inducer (EMMPRIN/ CD147) in Pancreatic Neoplasm and Pancreatic Stellate Cells. Cancer Biol Therapy 2007;6:e1-e10.